Presentation is loading. Please wait.

Presentation is loading. Please wait.

A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib  Oliver Gautschi, MD, Chantal Pauli, MD, Klaus Strobel, MD, Astrid Hirschmann,

Published byRobert Jonasson Modified over 5 years ago

Similar presentations

Presentation on theme: "A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib  Oliver Gautschi, MD, Chantal Pauli, MD, Klaus Strobel, MD, Astrid Hirschmann,"— Presentation transcript:

1 A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib 
Oliver Gautschi, MD, Chantal Pauli, MD, Klaus Strobel, MD, Astrid Hirschmann, Gert Printzen, MD, Stefan Aebi, MD, Joachim Diebold, MD  Journal of Thoracic Oncology  Volume 7, Issue 10, Pages e23-e24 (October 2012) DOI: /JTO.0b013e Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 A, CT scan at diagnosis with a tumor in the left lung (long arrow), mediastinal lymph node metastases (short arrow), left pleural effusion (arrowheads), and pericardial effusion; (B) pretreatment FDG-PET/CT with increased FDG uptake (SUV max. 13.3) in the lung tumor (long arrow) and the mediastinal nodes (SUV max. 15.0, short arrow), and pleural effusion (arrowheads); and (C) follow-up FDG-PET/CT after 2 weeks of vemurafenib with decreased uptake in the lung tumor (SUV max. 5.5, long arrow) and in the mediastinal nodes (SUV max. 6.2, short arrow). CT, computed tomography; FDG, fluorodeoxyglucose; PET, positron emission tomography; SUV max., maximum standardized uptake value. Journal of Thoracic Oncology 2012 7, e23-e24DOI: ( /JTO.0b013e ) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 A, Diagnostic cytology with thyroid transcription factor-1–positive cancer cells and (B) Sanger sequencing read with heterozygous T-A mutation (arrow) in codon 600 of BRAF. C Autopsy with macroscopic appearance of tumor fibrosis in the left lung (arrow) and (D) representative histopathology section with residual tumor cell islet (arrow) surrounded by fibrotic tissue (arrowheads), consistent with significant tumor regression after vemurafenib therapy. Journal of Thoracic Oncology 2012 7, e23-e24DOI: ( /JTO.0b013e ) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "A Patient With BRAF V600E Lung Adenocarcinoma Responding to Vemurafenib  Oliver Gautschi, MD, Chantal Pauli, MD, Klaus Strobel, MD, Astrid Hirschmann,"

Similar presentations

Malignant Triton Tumor of the Brachial Plexus Invading the Left Thoracic Inlet: A Rare Differential Diagnosis of Pancoast Tumor  Jo Dartnell, BSc, MRCS,

Malignant Triton Tumor of the Brachial Plexus Invading the Left Thoracic Inlet: A Rare Differential Diagnosis of Pancoast Tumor  Jo Dartnell, BSc, MRCS,
Jeffrey Bradley, MD  Journal of Thoracic Oncology 

Jeffrey Bradley, MD  Journal of Thoracic Oncology 
Marked Tumor Response and Fatal Hemoptysis During Radiation for Lung Cancer in a Human Immunodeficiency Virus-Positive Patient Taking Nelfinavir  Christopher.

Marked Tumor Response and Fatal Hemoptysis During Radiation for Lung Cancer in a Human Immunodeficiency Virus-Positive Patient Taking Nelfinavir  Christopher.
The Role of Extended Cervical Mediastinoscopy in Staging of Non-small Cell Lung Cancer of the Left Lung and a Comparison with Integrated Positron Emission.

The Role of Extended Cervical Mediastinoscopy in Staging of Non-small Cell Lung Cancer of the Left Lung and a Comparison with Integrated Positron Emission.
FDG PET-CT Aids in the Preoperative Assessment of Patients with Newly Diagnosed Thymic Epithelial Malignancies  Marcelo F.K. Benveniste, MD, Cesar A.

FDG PET-CT Aids in the Preoperative Assessment of Patients with Newly Diagnosed Thymic Epithelial Malignancies  Marcelo F.K. Benveniste, MD, Cesar A.
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography  Walter.

Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography  Walter.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Diffusion-weighted magnetic resonance imaging in preoperative assessment of non– small cell lung cancer  Hiroaki Nomori, MD, Yue Cong, MD, Masaru Abe,

Diffusion-weighted magnetic resonance imaging in preoperative assessment of non– small cell lung cancer  Hiroaki Nomori, MD, Yue Cong, MD, Masaru Abe,
Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer  Ernest Nadal,

Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer  Ernest Nadal,
BRAF V600E Mutation Is not Always Present as Expected

BRAF V600E Mutation Is not Always Present as Expected
Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802)

Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH /RO )
Diagnostic Performance of Integrated Positron Emission Tomography/Computed Tomography for Mediastinal Lymph Node Staging in Non-small Cell Lung Cancer:

Diagnostic Performance of Integrated Positron Emission Tomography/Computed Tomography for Mediastinal Lymph Node Staging in Non-small Cell Lung Cancer:
Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma  Filippo Gustavo Dall’Olio, MD, Celeste.

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma  Filippo Gustavo Dall’Olio, MD, Celeste.
Exogenous Lipoid Pneumonia Mimicking Multifocal Bronchogenic Carcinoma

Exogenous Lipoid Pneumonia Mimicking Multifocal Bronchogenic Carcinoma
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea  Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,

Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea  Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,
Zeynep Eroglu, MD, Jae Kim, MD, Sharon Wilczynski, MD, PhD, Warren A

Zeynep Eroglu, MD, Jae Kim, MD, Sharon Wilczynski, MD, PhD, Warren A

Similar presentations

Ads by Google